Stock-Based Compensation for Alnylam Pharmaceuticals (ALNY)
Stock-Based Compensation for Alnylam Pharmaceuticals (ALNY): headline value $276.60M · YoY +28.0%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingStock-Based CompensationSwitch metric
Latest period
$276.60M
YoY change
+28.0%
5Y CAGR
+20.0%
Peak year (2025)
$348.24M
Latest annual
$348.24M
Stock-Based Compensation history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Stock-Based Compensation history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| Fiscal year | Period ended | Reported | Stock-Based Compensation | YoY |
|---|---|---|---|---|
| 2025 | $348.24M | +28.0% | ||
| 2024 | $272.08M | +22.7% | ||
| 2023 | $221.68M | -3.9% | ||
| 2022 | $230.65M | +39.2% | ||
| 2021 | $165.72M | +18.5% | ||
| 2020 | $139.87M | -20.0% | ||
| 2019 | $174.84M | +10.8% | ||
| 2018 | $157.75M | +70.0% | ||
| 2017 | $92.82M | +22.9% | ||
| 2016 | $75.53M | +65.0% | ||
| 2015 | $45.78M | +38.5% | ||
| 2014 | $33.06M | +59.7% | ||
| 2013 | $20.70M | +67.5% | ||
| 2012 | $12.36M | -26.4% | ||
| 2011 | $16.80M | -13.1% | ||
| 2010 | $19.34M | -4.1% | ||
| 2009 | $20.17M | +11.9% | ||
| 2008 | $18.03M | +24.6% | ||
| 2007 | $14.47M | +74.3% | ||
| 2006 | $8.30M | — | ||
| 2005 | $0 | -100.0% | ||
| 2004 | $4.11M | — | ||
| 2003 | $0 | — | ||
| 2002 | $0 | — |
Stock-Based Compensation values are taken from Alnylam Pharmaceuticals's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
The 2025 reading of Alnylam Pharmaceuticals (ALNY) stock-based compensation is $348.24M – grew 28.0% year-over-year.
Alnylam Pharmaceuticals stock-based compensation compound annual growth for the 2020–2025 (5 years) window is +20.0%, with the latest reading among the more recent periods of the dataset.
$348.24M stands as the all-time-high annual stock-based compensation, posted in 2025, against a low of $0 during 2002.
Within Healthcare, Alnylam Pharmaceuticals (ALNY) ranks 5th among 8 peers we track. The peer median for stock-based compensation is $313.00M.
Alnylam Pharmaceuticals Stock-Based Compensation by Year
Alnylam Pharmaceuticals Stock-Based Compensation 2025: $348.24M
Alnylam Pharmaceuticals stock-based compensation in 2025 was $348.24M, grew 28.0% from 2024. This figure represents the highest annual value in the available history.
Alnylam Pharmaceuticals Stock-Based Compensation 2024: $272.08M
Alnylam Pharmaceuticals stock-based compensation in 2024 was $272.08M, grew 22.7% from 2023.
Alnylam Pharmaceuticals Stock-Based Compensation 2023: $221.68M
Alnylam Pharmaceuticals stock-based compensation in 2023 was $221.68M, edged down 3.9% below 2022.
Alnylam Pharmaceuticals Stock-Based Compensation 2022: $230.65M
Alnylam Pharmaceuticals stock-based compensation in 2022 was $230.65M, surged 39.2% from 2021.
Alnylam Pharmaceuticals Stock-Based Compensation 2021: $165.72M
Alnylam Pharmaceuticals stock-based compensation in 2021 was $165.72M.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers — Stock-Based Compensation
Companies in the same sector as Alnylam Pharmaceuticals, ranked by their latest stock-based compensation.
| Company | Stock-Based Compensation | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $1.35B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $971.00M | Healthcare |
| AbbVie Inc. (ABBV) | $955.00M | Healthcare |
| Eli Lilly and Company (LLY) | $626.00M | Healthcare |
| AstraZeneca PLC (AZN) | $0 | Healthcare |
| Merck & Co., Inc. (MRK) | $0 | Healthcare |
| Amgen Inc. (AMGN) | $0 | Healthcare |
| Novo Nordisk A/S (NVO) | $0 | Healthcare |
Frequently asked questions
What is Alnylam Pharmaceuticals's stock-based compensation?
Latest reported stock-based compensation for Alnylam Pharmaceuticals (ALNY) is $276.60M (period ending December 31, 2025).
How has Alnylam Pharmaceuticals stock-based compensation changed year-over-year?
Alnylam Pharmaceuticals (ALNY) stock-based compensation changed +28.0% year-over-year on the latest annual filing.
What is the long-term growth rate of Alnylam Pharmaceuticals stock-based compensation?
Alnylam Pharmaceuticals (ALNY) stock-based compensation compound annual growth rate is +20.0% over the most recent 5 years available.
When did Alnylam Pharmaceuticals stock-based compensation hit its highest annual value?
Alnylam Pharmaceuticals stock-based compensation reached its highest annual value of $348.24M in 2025.
What was Alnylam Pharmaceuticals stock-based compensation in 2024?
Alnylam Pharmaceuticals (ALNY) stock-based compensation in 2024 was $272.08M.
What was Alnylam Pharmaceuticals stock-based compensation in 2025?
Alnylam Pharmaceuticals (ALNY) stock-based compensation in 2025 was $348.24M.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
ALNY Overview
Company profile, financial tools, and key metrics
ALNY Revenue Counter
Earns $117.77 every second. See per minute, hour, and day.
ALNY Earnings Counter
Earns $9.95 per second net profit. See per minute, hour, and day.
ALNY Economic Scale
Exceeds Curacao's GDP. Compare with world economies.
ALNY What If Invested
What if you had invested $1,000? See historical returns from any date.
ALNY How It Makes Money
Discover visual breakdown of $3.71B in revenue — where it comes from and where it goes.
ALNY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
ALNY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
ALNY Daily Price Character
Explosive · 50.6% historical win rate (green days). Streaks & record days.
ALNY Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.